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The physical reactions to hematopoietic stem cell donation have been extensively studied, but less is known
about factors that predict poorer donation experiences. The aim of this prospective study was to examine
demographic and health-related quality of life (HRQOL) factors that might be associated with recovery and
side effects. We also described the changes in HRQOL during the donation process. In total, 275 peripheral
blood stem cell (PBSC) and 37 bone marrow (BM) consecutive donors completed the SF-36 questionnaire
predonation and 4 weeks, and 3 months postdonation. Predonation HRQOL markers were the strongest
predictors of time to recovery. Poorer predonation physical health was associated with longer recovery
(P ¼ .017) and certain side effects in PBSC donors. Poorer predonation mental health was associated with
longer recovery in BM donors (P ¼ .03) and pain after PBSC donation (P ¼ .003). Physical HRQOL scores
declined signiﬁcantly from predonation to 4 weeks postdonation. This was shown both for PBSC and BM
donors (P < .001 and P ¼ .009, respectively), but the decline was much greater for BM donors. There was a
return to predonation HRQOL values 3 months after donation in both groups with values well above the mean
of the general population (P < .001).
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation is a curative
procedure for life-threatening hematological diseases. Dur-
ing the last decade, peripheral blood stem cells (PBSCs) have
replaced bone marrow (BM) as the main source of hemato-
poietic stem cells. Although the donation process is generally
considered safe, side effects are a known risk, and care must
be taken to minimize the potential of harm to donors.
Common side effects of BM and PBSC donation are well
known [1-6], although studies examining which groups of
donors are at increased risk are limited [3,5-13]. The latter is
important because strategies to enhance donor safety should
be based on ﬁndings from these studies and could result in a
more personalized approach to higher risk groups. Research
in orthopedic surgery has shown a signiﬁcant relationshipedgments on page 356.
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ty for Blood and Marrow Transplantation.between preoperative health-related quality of life (HRQOL)
and recovery [14,15]. Speciﬁcally, negative mood was shown
to exacerbate pain. Given that pain is the most common side
effect in the peridonation period, investigation into the
relationship between predonation HRQOL and recovery may
also be relevant in this setting.
In this prospective study, we aimed to identify the factors
that inﬂuence donor recovery in a formal manner and those
that are most commonly associated with certain side effects.
We included both demographic factors and predonation
HRQOL scores using the Short-Form 36 Health Survey (SF-
36) questionnaire. We also describe the changes in HRQOL
predonation and up until 3 months after donation and
compare HRQOL between PBSC and BM donors.
METHODS
Study Population
The study population was composed of unrelated donors from the
United Kingdom whose BM or granulocyte colony-stimulating factor (G-
CSF)-mobilized PBSC donation was facilitated by Anthony Nolan between
February and November 2013. All donors passed a rigorous physical eligi-
bility screening (according to World Marrow Donor Association
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least 50 kg and a body mass index (BMI) < 35 for BM donors and <40 for
PBSC donors. Donors gave informed consent for the donation process as per
normal practice as well as additional informed consent for the HRQOL
assessment questionnaires. Ethical approval was obtained from the regis-
try’s institutional review board.
Stem Cell Collection Methods
All PBSC donors were mobilized with lenograstim (glycosylated G-CSF;
Chugai Pharma, London, UK), which was given at a once-daily dose of 10 mg/
kg subcutaneously  10% for 4 consecutive days, and apheresis was
commenced on day 5. A maximum of 2 apheresis procedures was per-
formed. Donors who donated BM underwent harvest from both iliac crests
under general anesthesia. In line with World Marrow Donor Association
guidelines, no more than 20 mL/kg donor weight was extracted. Both types
of donation were carried out in 1 of 4 collection centers.
Data Collection
Donors were recruited at the time of the donor’s medical evaluation,
which took place on average 17 days (range, 8 to 30) before donation. Data
collection continued on day 4, day 3, and day 2 before donation for
PBSC donors and on the day of collection for both types of participants (day
0). We subsequently contacted BM and PBSC donors via telephone 2 or
3 days after donation. Donors were contacted again using an online ques-
tionnaire 1 week after donation and weekly thereafter up until complete
recovery.
Complete recovery was determined on the day 2 to 3 or weekly ques-
tionnaire and deﬁned as the absence of ongoing symptoms as well as return
to predonation health. The assessment at each time point involved a self-
reported checklist of speciﬁc side effects, including allergy, anorexia, back
pain, bleeding, bruising, dizziness, fatigue, fever, headache, infection, in-
jection site reaction, insomnia, myalgia, nausea, any other pain, and vom-
iting. Each side effect was scored using the Common Terminology Criteria
for Adverse Events (CTCAE) toxicity index. Demographic factors analyzed as
potential inﬂuencing factors of time to recovery or side effects were gender,
age, BMI, support network (number of dependents, marital status), and
being a blood donor.
Health-Related Quality of Life
HRQOL was measured using the SF-36 questionnaire, given to donors
(either by post or e-mail) before donation (before the start of G-CSF for PBSC
donors) and 4 weeks and 3 months after donation. The SF-36 is a generic
indicator of HRQOL derived from the 245-item Medical Outcomes ques-
tionnaire. It includes multi-item scales to measure the following 8 di-
mensions: physical functioning (PF), role limitations due to physical health
problems (RP), bodily pain (BP), general health perception, vitality, social
functioning, role limitations due to emotional problems, and general mental
health. Physical Component Summary (PCS) and Mental Component Sum-
mary (MCS) scores provide a broad physical and mental health perspective
[17]. Norm-based scoring was used to interpret the different dimensions’
and summary scores [17,18]. This scoring is created by computing the 0 to
100 score for a scale and then adjusting this score by the general pop-
ulation’s average and standard deviation (SD) on that scale. As a conse-
quence, the populationmean and SD of all scores are 50 and 10, respectively,
with higher scores reﬂecting more positive health states.
Statistical Analysis
The primary endpoints were time to recovery and individual side effects
at different time points as deﬁned earlier. Characteristics analyzed as po-
tential inﬂuencing factors were the previously deﬁned demographic factors
and the PCS and MCS measures.
The probabilities of complete recovery were calculated using the
Kaplan-Meier estimator, and groups were compared using the log rank test.
PCS andMCSmeasures were split into 4 groups, based on the 25th, 50th, and
75th percentiles. Factors signiﬁcant in univariate analysis at the .20 level
were entered into a stepwise proportional hazards regression analysis.
The inﬂuence of the previously deﬁned demographic and HRQOL factors
on individual side effects was examined using either a chi-square test, t-test,
or Mann-Whitney U test. Binary summary scores were established for pain
(headache, myalgia, back pain, and any other pain) and any side effect for
each time point. In addition, summary scores for each side effect involving
all time points from day 0 onward were established. Factors with P  .20 in
the univariate analysis were included in a stepwise logistic regression
analysis. Comparison between BM and PBSC donors was performed using
the chi-square test for categorical variables and the t-test or Mann-Whitney
U test for continuous variables.
Our secondary endpoint was to assess changes in SF-36 scores before,
4 weeks after, and 3 months after donation. Paired sample t-tests were usedto compare the SF-36 scores before and after donation. Stepwise linear
regression analysis was performed to identify signiﬁcant variables that
could be used to predict HRQOL (using PCS and MCS scores) at 4 weeks after
donation.
All statistical analysis was performed using SPSS software (IBM,
Armonk, NY). A 2-tailed P < .05 was considered signiﬁcant.
RESULTS
Characteristics, Side Effects, and Recovery in BM and
PBSC Donors
Table 1 shows clinical characteristics of BM and PBSC
donors enrolled in the study. A central linewas inserted in 5%
of PBSC donors (2% of male donors compared with 15% of
female donors; P < .001); 27% of PBSC donors (74/275)
required a 2-day collection.
Figure 1 shows the time course and side effects experi-
enced in PBSC donors. Pain in PBSC donors consisted mainly
of bone pain and headache. Pain peaked during administra-
tion of G-CSF, with 85% of donors experiencing pain on the
third day of G-CSF administration. The pain was graded as
CTCAE 1 in 80% of cases, with only 1 donor experiencing
grade 3 pain. Fatigue and bruising were the other most
common side effects, peaking on days 2 and 3 after donation.
Seventy-ﬁve percent of donors (207/278) required analgesia
during G-CSF administration, and 2.5% of donors still
required analgesia 7 days after donation.
All BM donors received general anesthesia. The mean
duration of the procedure was 41 minutes (range, 20 to 120).
The mean volume of BM harvested was 1209 mL (range, 290
to 1740). Autologous units were not collected, and no donor
received an allogeneic transfusion. All except 1 were dis-
charged the day after BM harvest. Figure 2 shows the time
course and side effects experienced. Pain in BM donors was
generally localized to the site of donation or the throat (after
intubation). The peak of pain was reported on days 2 and 3
after donation for back pain (76.5%) and on the day of
donation for throat pain (48.6%). Fatigue and bruising were
the most common other side effects reactions, peaking on
days 2 and 3 after donation. Most side effects were classiﬁed
as CTCAE grade 1, and no donor experienced grade 3 or 4 side
effects in this small cohort. Ten percent of BM donors (3/29)
still required analgesia 1 week after donation.
The median time to recovery for BM donors was 10 days
as opposed to 3 days for PBSC donors (P ¼ .001) (Figure 3A).
Only 50% of BM donors believed they had recovered after
1 week, and 68.8% had returned to work, compared with
90.3% and 98.3% of PBSC donors, respectively (P < .001).
Compared with PBSC donors, signiﬁcantly more BM donors
still experienced pain (P < .001) and other side effects in
general (P < .001) 1 week after donation.
Health-Related Quality of Life
The response rates for the SF-36 questionnaires for PBSC
donors were 72% (198/275) before donation, 72% (199/275)
4 weeks after, and 72% (198/275) 3 months after donation.
Fifty-eight percent of PBSC donors returned all 3 question-
naires. Nonparticipants were more likely to be younger
(P < .001) and male (P < .05). There was no statistical dif-
ference between collection characteristics in those returning
versus not returning forms. This included volume of blood
processed, presence of a central line, and 1- versus 2-day
collection.
The response rates for the questionnaires for BM donors
were 75% (28/37) before donation, 59.5% (22/37) 4 weeks
after donation, and 67.6% (25/37) 3 months after donation.
Forty-nine percent of BM donors (18/37) returned all 3
Table 1
Donor Characteristics at Time of Donation for PBSC and BM Donors
Characteristic PBSC BM
n % n %
Number of donors 275 88 37 12
Number of apheresis/
harvest centers
4 4
Gender
Male 209 76 34 89
Female 65 24 4 11
Ethnicity
United Kingdom
and Ireland
99 36 11 29
Europe (White) 160 58 23 61
Other (White) 4 2 1 2
Asian 3 1 0 0
African and Caribbean 2 .5 1 2
Mixed ethnicity 2 .5 0 0
Decline/unknown 4 2 2 6
Donor age at donation
16-30 yr 122 44.5 21 55
31-40 yr 92 33.5 7 18
41-63 yr 60 22 10 27
Median (range) 30.9 (17-63) 27.9 (19-55)
Donor BMI
Underweight (<18.5) 3 1 0 0
Normal (18.5-24.9) 100 38 14 37
Overweight (25-29.9) 107 41 14 37
Obese (>30) 53 20 10 26
Median (range) 25.9 (17-41.6) 26.7 (19.7-33.9)
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demographic factors and collection characteristics (duration
of harvest, marrow harvested per unit of donor’s weight) in
those returning versus not returning forms.
Factors Affecting Time to Complete Recovery
PBSC donors
Factors associated with a more rapid recovery time in
univariate analyses were a higher predonation PCS score
(P ¼ .002) (Figure 3B), younger age (P ¼ .003), and maleFigure 1. Frequency of common sidgender (P ¼ .027). The mean time to complete recovery was
5.8 days (range, 0 to 30) for donors with predonation PCS
scores  56 (lowest quartile) compared with 3 days (range,
0 to 21) for donors with scores > 60 (highest quartile). A
difference in time to complete recovery was most signiﬁcant
when comparing the donors with scores in the lowest
quartile with the other groups. When assessing the individ-
ual components of the PCS, higher PF (P < .01), RP (P < .05),
and less BP (P ¼ .005) were associated with a more rapid
recovery. There was no signiﬁcant association between BMI
(P ¼ .99), marital status (P ¼ .21), being a blood donor
(P ¼ .37), predonation MCS score (P ¼ .29), blood volume
processed (P ¼ .65), and recovery. Donors with fewer de-
pendents showed a trend toward more rapid recovery
compared with donors with more dependents (P ¼ .057).
When assessing the association between collection charac-
teristics and a faster recovery, there was a trend toward
signiﬁcance for the absence of a central line (P¼ .068) and 1-
versus 2-day collection (P¼ .084). The predonation PCS score
was the only factor that remained signiﬁcant in multivariate
analysis (P ¼ .017). Donors with a predonation PCS higher
than 60 (highest quartile) had a relative risk of 1.6 (95%
conﬁdence interval [CI], 1.01 to 2.7) of achieving faster re-
covery compared with donors with scores  56 (lowest
quartile).BM donors
The only factor inﬂuencing time to recovery in univariate
analysis was the predonation mental component summary
score (P ¼ .046) (Figure 3C); The mean time to complete
recovery was 28 days (range, 4 to 56) for donors with pre-
donation MCS scores  46 (lowest quartile) compared with
9.4 days (range, 2 to 21) for donors with scores > 58 (highest
quartile). Again, this difference in time to complete recovery
was most signiﬁcant when comparing the donors with
scores in the lowest quartile with the other groups. There
was no signiﬁcant association between gender (P ¼ .17), age
(P ¼ .42), BMI (P ¼ .88), number of dependents (P ¼ .31)e effects after PBSC donation.
Figure 2. Frequency of common side effects after BM donation.
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time to recovery. Time of procedure (P ¼ .25) and volume of
harvest per kilogram recipient weight (P ¼ .95) were notFigure 3. (A) Probability of self-reported complete recovery after PBSC versus BM do
impact of the PCS score. (C) Probability of self-reported complete recovery after BMsigniﬁcantly associated with recovery. In multivariate anal-
ysis, predonation MCS scores (P¼ .026) remained signiﬁcant.
Donors with predonation MCS scores> 46 had a relative risknation. (B) Probability of self-reported complete recovery after PBSC donation,
donation, impact of the MCS score.
Table 2
Changes in Predonation and Postdonation Scores
Type of Donation Scoring Type Mean of Difference Between Score
at 4 Weeks and Baseline (Range)
P Mean of Difference Between Score
at 3 Months and Baseline (Range)
P
PBSC PCS .92 (14.9 to 13.2) <.001* .009 (12.5 to 16.0) .98y
MCS .2 (26.3 to 29.5) .641 .1 (19.5 to 21.2) .79y
BM PCS 5.02 (18.4 to 8.6) .009z .3 (12.2 to 9.6) .71x
MCS 3.9 (28.5 to 9.5) .017z 1.2 (21.0 to 7.4) .37x
* Calculated comparing pairs with predonation and 4-week scores (n ¼ 169).
y Calculated comparing pairs with predonation and 3-month scores (n ¼ 151).
z Calculated comparing pairs with predonation and 4-week scores (n ¼ 18).
x Calculated comparing pairs with predonation and 3-month scores (n ¼ 23).
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compared with donors with scores  46 (lowest quartile).Table 3
General Health Questionnaires in BM versus PBSC DonorsMultivariate Analysis of Factors Affecting Individual Side
Effects at Different Time Points in PBSC Donors
Physical component summary
Donors with predonation SF-36 PCS scores in the lowest
quartile were more likely to experience fatigue (odds ratio
[OR] 4.7; 95% CI, 1.8 to 12.7; P ¼ .002) or any side effect (OR
3.0; 95% CI, 1.1 to 8.5; P¼ .03) on days 2 and 3 compared with
donors with PCS scores in the highest quartile. They were
also more likely to experience pain at any time point (OR 5.6;
95% CI, 1.8 to 17.6; P < .005).
Mental component summary
Donors with a predonation MCS score in the lowest
quartile were more likely to experience pain at any time
point compared with donors with scores in the highest
quartile (OR 2.8; 95% CI, 1.1 to 7.1; P ¼ .003). Dizziness at any
time point was alsomore common in donors with lowerMCS
scores (OR 2.3; 95% CI, 1.01 to 5.5; P ¼ .003).Time Point Dimension BM
Mean
PBSC
Mean
P
Predonation PF 56.0 56.8 .13
RP 56.7 56.5 .61
BP 58.4 57.0 .28
General health perception 56.7 57.8 .42
Vitality 54.2 55.5 .42
Social functioning 54.6 55.9 .11
Role limitations due to
emotional problems
52.8 54.8 .07
General mental health 52.6 54.6 .08
PCS 58.3 57.5 .29
MCS 52.0 54.1 .24
4 weeks after
donation
PF 47.0 52.9 .001
RP 41.9 50.9 <.001
BP 44.1 53.1 .002
General health perception 48.5 53.6 .14
Vitality 42.4 51.2 .01
Social functioning 42.5 51.8 .001
Role limitations due to
emotional problems
43.1 51.4 .007
General mental health 45.0 51.2 .32
PCS 45.1 51.8 .003
MCS 42.4 49.1 .34
3 months after
donation
PF 56.1 56.2 .90
RP 56.7 56.0 .27
BP 58.2 58.3 .93
General health perception 58.2 57.2 .57
Vitality 55.9 54.8 .55
Social functioning 54.1 54.7 .74
Role limitations due to
emotional problems
53.0 54.8 .12
General mental health 54.1 54.1 .98
PCS 58.2 57.8 .64
MCS 52.6 53.6 .47Changes in SF-36 Score from Predonation Through
4 Weeks and 3 Months Postdonation
As indicated in Table 2, PCS scores declined signiﬁcantly
from predonation to 4 weeks postdonation (P < .001), with a
return to predonation values at 3 months. This was shown
both for PBSC and BM donors, but the decline in PCS scores
was much greater for BM donors (Table 3). At 4 weeks after
donation, the PF (P ¼ .001), PR (P < .001), and BP (P ¼ .002)
subscores were lower for BM donors compared with PBSC
donors. Mental summary score did not change throughout
donation for PBSC donors but was signiﬁcantly lower at
4 weeks for BM donors (P < .01); this returned to normal
levels at 3 months.
The most signiﬁcant subscore change in PBSC donors was
for the RP score with a mean difference between the 4-week
score and predonation of 1.6 (P < .001). The most signiﬁ-
cant subscore changes in BM donors were within the phys-
ical scores with a mean difference between the 4-week and
predonation score of 7.8 (P ¼ .004) for RP, followed by a
mean difference of 5.8 (P ¼ .021) for BP and a mean dif-
ference of 1.5 (P ¼ .049) for PF. The most signiﬁcant dif-
ference between the predonation and 4-week score within
the mental scores in BM donors was for vitality scores, with a
mean difference of -8.1 (P < .001), followed by a mean dif-
ference of -6.0 (P=.001) for SF.. There were no changes in
general health perception (P ¼ .27), emotional problems
(P ¼ .074), or general mental health score (P ¼ .42).Factors Predicting Physical and Emotional Health
4 Weeks after PBSC Donation
Based on the ﬁnding that HRQOL is signiﬁcantly affected
4 weeks after donation, we aimed to clarify whether we
could establish predictive factors for PCS and MCS scores
4 weeks after donation using multivariate linear regression
analysis. We found no demographic factors were predictive
of HRQOL after donation. Only a lower predonation PCS
(coefﬁcient b .64; 95% CI, .44 to .84; P < .001) and experi-
encing any kind of pain 2 and3 days after donation (coefﬁ-
cient b 1.721; 95% CI, 3.2 to .2; P ¼ .03) were associated
with lower PCS outcomes at 4 weeks in PBSC donors.
Explanatory variables included gender, age, BMI, number of
dependents, marital status, being a blood donor, predonation
PCS score, any side effect on days 2 and 3 summary score, and
any pain on days 2 and 3.
Similarly, a lower predonation MCS score (coefﬁcient b
.71; 95% CI, .53 to .87; P < .001) and experiencing any kind of
A. Billen et al. / Biol Blood Marrow Transplant 21 (2015) 350e356 355pain 2 and 3 days after donation (coefﬁcient b 2.2; 95%
CI; 4.3 to .18; P ¼ .01) were associated with lower MCS
outcomes at 4 weeks. Explanatory variables included gender,
age, BMI, number of dependents, marital status, being a
blood donor, predonation MCS score, any side effect on days
2 and 3 summary score, and any pain on days 2 and 3.
DISCUSSION
Voluntary donation of BM or PBSC for hematopoietic cell
transplantation is awell-established altruistic act, performed
by thousands of healthy related or unrelated donors
throughout the world. Although allogeneic stem cell dona-
tion is a safe procedurewith very low rates of serious adverse
reactions, some risk exists, and every effort should be made
to minimize this.
In this prospective study, we found that predonation
HRQOL markers were the most important factors associated
with recovery and the development of side effects, more so
than any demographic variable. To our knowledge, no studies
have addressed the impact of predonation HRQOL on the
donation experience in hematopoietic stem cell donors. The
response rates of predonation HRQOL questionnaires were
very acceptable (72%) in this study and better comparedwith
another study in this ﬁeld using the SF-36 questionnaire
(60%) [19]. Response rates of a more recent study from
Switzer et al. [20], however, were better compared with our
study (99%), likely because the studymethodologies differed.
The SF-36 questionnaire is the most widely used health
status assessment tool in clinical trials [21]. The reason for
choosing the SF-36 over the SF-12 or SF-8 questionnaire,
which are shorter surveys and can be completed quicker, is
because more items permit better precision and represen-
tation of each health domain [22].
The importance of PCS and MCS was demonstrated with
quartiles providing cut-points. If treated as continuous var-
iables, signiﬁcant results were also obtained (data not
shown). A lower predonation PCS score was the main factor
associated with recovery for PBSC donors in multivariate
analysis. Three scales (PF, RP, and BP) correlate most strongly
with the physical component and contribute most to scoring
of the PCS measure. Lower PCS scores indicate more limita-
tions in PF, RP, a higher degree of BP, and poorer self-reported
general health. Interestingly, mean predonation PCS scores
were well above the mean of the general population (þ.76
SD; P < .001), reﬂecting the strict medical assessment of
donors. Examples of reasons for lower predonation PCS
scores in this cohort included mild limitations to perform
work or vigorous activities or having a history of mild or
moderate bodily pains. Despite these mild limitations, lower
predonation PCS scores were associated with a slower re-
covery. Experiencing very common side effects, such as pain
and fatigue, were also associated with a lower predonation
PCS score.
Lower predonation MCS scores were associated with an
increased likelihood of experiencing pain in PBSC donors.
Similar to the PCS scores, meanpredonationMCS scoreswere
above the mean of the general population (þ.41 SD;
P < .001). For the MCS measure, a lower score is indicative of
more frequent psychological distress, social and role
disability because of emotional problems, and poorer general
health. Examples of reasons for lower predonation MCS
scores in this cohort included feeling nervous, downhearted,
or worn out a lot of the time. A negative association between
mental or emotional health and an altered pain experience
has been described previously [14,15,23-28]. Moreover,psychosocial interventions are often part of a multimodal
approach of the management of pain [28], and negative
mood has emerged as a strong and reliable predictor of
postoperative outcomes [26].
We found similar results in our BM cohort; a lower pre-
donation MCS score was the most important factor associ-
ated with delayed recovery. A possible explanation of the
ﬁnding that MCS scores predicted recovery in BM donors but
not in PBSC donors may be related to the very distinct nature
of the 2 procedures. Because BM donation was associated
with pain symptoms at later time points, we speculate that
preexisting symptoms of anxiety or low mood would have a
signiﬁcant impact on this outcome.
When examining the evolution of HRQOL during the
donation process, we found a decrease in general health for
BM and PBSC donors at 4 weeks with a return to normal
levels 3 months after donation. The 3-month values were
well above the mean of the general population (þ.79 SD for
PCS and þ.34 SD for MCS; P < .001). Most scores at 4 weeks
were signiﬁcantly lower for BM donors compared with PBSC
donors, reﬂecting a delayed recovery compared with PBSC
donors [4,6,19,29,30]. We did not ﬁnd improved mental or
physical scores after donation, as described in a recent study
[20]. This may be related to the different time points
assessed; improved physical and mental scores were
described at 6 and 12 months after donation. We may have
possibly observed a similar trend if we had continued as-
sessments at these time points.
To the best of our knowledge, this is the ﬁrst study to
show that even in PBSC donors, physical health is signiﬁ-
cantly (although minimally) reduced 4 weeks after donation
compared with predonation. The strongest decrease was
within the RP subscore. The RP scale covers an array of
physical health-related role limitations, including limitations
and reductions in the amount of time spent at work or other
activities (such as sports). There were no signiﬁcant changes
in MCS scores during the donation process for PBSC donors,
as opposed to BM donors. The main MCS subscore affected in
BM donors was the vitality score. These ﬁndings may reﬂect
an association between physical morbidity and vitality and
are in keeping with a delayed physical recovery in BM versus
PBSC donors. Despite considerable pain in BM donors,
mental health scores remained high, indicating that donors
did not feel distressed by pain. This had also been previously
reported [31]. In view of these ﬁndings, we would recom-
mend the donor experience to be a serious consideration
when deciding on the stem cell source, especially if there is
no speciﬁc patient indication for a BM source.
Based on the ﬁnding that HRQOL was signiﬁcantly
decreased at 4 weeks, we aimed to predict which side effects
were associated with poorer outcomes. We found that
experiencing pain on days 2 and 3 was a signiﬁcant predictor
of general physical and mental health at 4 weeks after
donation in PBSC donors, regardless of predonation physical
and mental health. This information could be very valuable
to monitor this high-risk group more closely.
However, certain limitations in our study must be
acknowledged: The SF-36 only captures part of overall
HRQOL, and a more comprehensive psychological assess-
ment tool or formal qualitative interview process must be
the focus of future studies. Also, we included a limited
number of BM donors, which limited the analysis in this
group. For example, the number of BM donor participants
was too small to analyze the factors affecting individual side
effects at different time points and to assess the factors
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after donation, 2 analyses that were performed in our PBSC
cohort.
In conclusion, we found that predonation quality of life
markers contribute signiﬁcantly to recovery and toxicity
proﬁle after BM or PBSC donation. We believe our ﬁndings
may help clinicians identify donors at risk for poorer out-
comes. HRQOL questionnaires such as the SF-36 are highly
standardized, and their introduction at the time of donor
medical evaluation should be considered to establish which
donors are at risk of delayed recovery. The ﬁndings of this
study may help clinicians provide donors with a targeted
guidance protocol. Possible interventions for high-risk do-
nors may include the use of preemptive analgesia, an
approach that has proven effective in BM donors [32] and
general surgery patients [33,34]. Preoperative patient edu-
cation has also demonstrated improved recovery times in
surgery [35,36]. These approaches, as well as a more strin-
gent follow-up of high-risk donors, need to be examined in
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